It has been suggested that GBM can be classified into molecular subtypes: variants with somatic mutations in isocitrate dehydrogenase 1 (IDH1), isocitrate dehydrogenase 2 (IDH2), or tumour protein 53 (TP53); transcriptional signature; copy-number variation; amplification or mutation of epidermal growth factor receptor (EGFR), and hypermethylation of promoter regions [5]. This evidence concerns the gene EGFR and glioblastoma.